Seattle, WA -- (SBWIRE) -- 11/11/2019 -- Global Dilated cardiomyopathy (DCM) is a condition, in which the heart's ability to pump blood is decreased due to enlarging of heart's main pumping chamber. This can affect the functioning of other organs such as lungs, liver, and kidney. In this disease, the heart muscles begin to dilate (stretch), which results in thinning and elongation of the chamber. In fact, it further spreads to the right ventricle and atria's. Due to this, normal contraction of heart muscles hinders and so does the normal pumping of blood. Furthermore, heart becomes weak, which can ultimately leads to heart failure. The symptoms such as fatigue, edema in ankles, legs, feet, veins in the neck and abdomen are quite common in this case. There are various reasons for dilated cardiomyopathy are uncontrolled blood pressure, viral infection, excessive amount of alcohol, and problem with heart valve. Although there is no proper drug to control DCM, doctors prescribe congestive heart failure drugs for its treatment. DCM is majorly found in people of age group 20-60 years old and very seldom in children. It is primarily diagnosed with electrocardiogram, X-ray, and MRI. Implantable devices such as 'Implantable Cardioverter Defibrillator (ICD) and pacemaker are implanted in the high risk patients, in order to maintain the proper rhythmic functioning of the heart so as to avoid risk of cardiac arrest. According to British Heart Foundation, in 2015, there were around 25,000 implants of pacemaker implanted every year in the U.K.
Download A Readymade Sample PDF Copy: https://www.coherentmarketinsights.com/insight/request-sample/514
Rise in congestive heart failure to drive growth of the global dilated cardiomyopathy market
Growing prevalence of congestive heart failure cases, which leads to the increase in dilated cardiomyopathy cases is expected to drive the market growth. According to American Heart Association, in 2016, there were around 5.7 million adults in the U.S. who suffered from heart failure. However, there is no drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of dilated cardiomyopathy. Moreover, key companies in the market are investing in research and development of new drugs such as ARRY-797 and Ixmyelocel-T, which is expected to support the growth of dilated cardiomyopathy market.
Market Restraints
However, increased use of defibrillators, pacemaker, and lack of proper drugs is expected to restrain growth of the global dilated cardiomyopathy market
Get PDF Brochure of This Business Report: https://www.coherentmarketinsights.com/insight/request-pdf/514
Developed regions are major growth engine of the global dilated cardiomyopathy market
Global dilated cardiomyopathy market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East and Africa. Among regions, North America holds the significant share in the global dilated cardiomyopathy market, owing to increase in congestive heart failure cases in the region. Furthermore, Europe accounts for the second largest in the market. According to, European Heart Network 2017 report, there are around 3.9 million deaths caused by cardiovascular disease in Europe and over 1.8 million deaths in the Europe Union. Furthermore, Asia Pacific is the third largest market and expected to grow at a higher rate due to increased awareness of cardiovascular disease and demand of generic drugs is expected to support the growth of the market
Key players of global dilated cardiomyopathy market
There are various players in the global dilated cardiomyopathy market present across the globe, which contributes to the DCM market. Some key players are Pfizer Inc., Johnson & Johnson Pvt. Ltd., Array BioPharma, AstraZeneca, GlaxoSmithKline Plc., and Sanofi.
In-Depth Study of TOC & Direct Purchase Report @ https://www.coherentmarketinsights.com/insight/buy-now/514
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.